ImmunoClin Corporation (OTC Markets: IMCL), a healthcare company specialized in personalized medicine, announces that its wholly owned subsidiary, ImmunoClin Ltd., received a controlled drug license from the UK government to possess, supply and produce schedule 1 drugs in its UK laboratory.
This license is essential to enable ImmunoClin to conduct research on cannabinoids in its London laboratory. Following the agreements announced last year, ImmunoClin will initiate formulation work that will include Cannabis Science, Inc. (CBIS) proprietary cannabinol (CBN) based product under development for neurological disorders. The Company is collaborating with the multinational company Unistraw Holdings Pte. Ltd. (Unistraw) and will utilize the Unistraw's pharmaceutical delivery system to prepare the product for pre-clinical testing.
"As announced last September, ImmunoClin has met its commitment; the preliminary results are expected within the next several months," said Dr. Dorothy Bray, CEO and President of ImmunoClin Corporation.